Gene splicing and gene therapy are fundamentally different things: one is a biological process (and a set of lab techniques for cutting and rearranging DNA or RNA), while the other is a medical treatment that delivers genetic material into a patient’s cells to treat disease. They overlap in important ways, and some therapies actually work by manipulating splicing, but the core distinction is that gene splicing is a mechanism and gene therapy is a clinical goal.
What Gene Splicing Actually Is
Gene splicing refers to the cutting and joining of genetic material. It happens in two very different contexts, and both get called “gene splicing,” which is part of the confusion.
The first is a natural process that occurs inside every one of your cells. When a gene is read to make a protein, the cell first produces a rough draft of RNA called pre-mRNA. This draft contains useful segments (exons) interspersed with segments the cell doesn’t need (introns). A large molecular machine called the spliceosome cuts out the introns, joins the exons together, and produces a finished RNA message that the cell can use to build a protein. This process happens billions of times a day in your body without any outside intervention.
The second context is a laboratory technique. Scientists use enzymes to cut DNA at precise locations and join segments together in new combinations. This is the basis of genetic engineering: you can take a gene from one organism, cut it out, and splice it into the DNA of another. More recently, tools like CRISPR-Cas9 have made it possible to edit DNA sequences directly inside living cells, correcting or disabling targeted sequences within the genome itself. This type of gene editing is sometimes loosely called gene splicing, though the mechanisms are quite different from the natural spliceosome process.
What Gene Therapy Does
Gene therapy is a medical treatment strategy. The goal is to treat or prevent disease by getting the right genetic instructions into a patient’s cells. The most established approach delivers a functional copy of a gene to compensate for one that is missing or defective. Rather than treating symptoms with drugs, gene therapy aims to address the root genetic cause.
Getting genetic material into cells is the central engineering challenge. Early gene therapy strategies used modified viruses as delivery vehicles, or vectors. Viruses are naturally good at inserting genetic material into cells, so researchers stripped out the disease-causing parts and loaded them with therapeutic genes instead. Common viral vectors include adeno-associated viruses (AAV), lentiviruses, and adenoviruses. Non-viral delivery methods have also emerged, including lipid nanoparticles (the same technology used in some COVID vaccines) and physical techniques that use electrical or mechanical energy to push genetic cargo through cell membranes.
Gene therapy doesn’t necessarily change your existing DNA. In many cases, the delivered gene sits alongside your original genome and simply produces the protein your body was missing. Gene editing, by contrast, involves altering the DNA itself, correcting the actual mutation. Both fall under the broader umbrella of genetic medicine, but they work through different mechanisms. Gene therapy adds something new; gene editing fixes what’s already there.
The Core Differences at a Glance
- Nature: Gene splicing is a process or technique. Gene therapy is a treatment.
- Goal: Gene splicing cuts and rearranges genetic material. Gene therapy delivers or corrects genetic instructions to treat disease.
- Scope: Gene splicing can happen naturally in your cells or be performed in a lab for research, agriculture, or medicine. Gene therapy is specifically a clinical intervention for patients.
- Tools: Natural splicing uses the spliceosome. Lab-based splicing and editing use restriction enzymes, ligases, or CRISPR. Gene therapy uses viral vectors, nanoparticles, or other delivery systems to get genetic material into cells.
Where the Two Overlap
Here’s where things get interesting: some gene therapies work by manipulating the splicing process itself. These treatments don’t deliver a new gene or edit DNA. Instead, they change how the cell’s spliceosome reads existing genetic instructions.
The clearest example is the treatment of spinal muscular atrophy (SMA). Patients with SMA lack a working copy of a gene called SMN1, which is critical for motor neurons. They do have a backup gene, SMN2, but the spliceosome typically skips a key section of SMN2’s RNA, producing a protein that’s too short to function. Nusinersen (brand name Spinraza) is a drug made of a short synthetic piece of genetic material that binds to the SMN2 pre-mRNA and blocks the signal that causes the spliceosome to skip that section. The result: the cell includes the missing section, produces a full-length protein, and motor neuron function improves. This is a gene therapy that works entirely through splicing modification.
A similar approach is used in Duchenne muscular dystrophy (DMD). In DMD, mutations in the dystrophin gene throw off the reading frame so that the cell can’t produce usable dystrophin protein. Exon-skipping drugs bind to the pre-mRNA and convince the spliceosome to skip over a specific exon neighboring the mutation. This brings the remaining exons back into the correct reading frame, producing a shorter but partially functional version of dystrophin. The resulting protein isn’t perfect, but it converts a severe condition into something closer to the milder Becker muscular dystrophy.
These splicing-based therapies sit right at the intersection of the two concepts. They use the cell’s natural splicing machinery as their mechanism, but their purpose is therapeutic. They don’t add new genes or edit DNA. They redirect a process that was already happening.
Safety Risks Differ Significantly
Natural gene splicing occasionally goes wrong on its own, and errors in splicing are linked to many diseases, including certain inherited skin conditions and cancers. But the safety concerns people typically ask about relate to the medical interventions.
Traditional gene therapy using viral vectors carries a specific risk called insertional mutagenesis. When a viral vector integrates its genetic cargo into a patient’s DNA, it can land in an unfortunate spot and accidentally switch on a cancer-promoting gene. This isn’t theoretical. In an early clinical trial for a severe immune deficiency called SCID-X1, several patients developed leukemia because the viral vector activated a gene called LMO2. In a separate trial for beta-thalassemia, an abnormal splicing event between the therapeutic gene and a nearby gene called HMGA2 caused uncontrolled cell growth. These events drove major efforts to develop safer vectors that are less likely to integrate in dangerous locations.
Gene editing tools like CRISPR carry a different risk profile. The primary concern is off-target effects, where the editing machinery cuts DNA at unintended sites in the genome. Splicing-based therapies like exon-skipping drugs tend to have a narrower risk profile because they work on RNA rather than DNA. RNA is temporary, so any unintended effects don’t permanently alter the genome.
Why the Distinction Matters
Understanding the difference helps you make sense of the rapidly expanding landscape of genetic medicine. When you read about a new gene therapy, it’s worth asking: does it deliver a new gene, edit existing DNA, or redirect splicing? Each approach has different implications for how long the treatment lasts, what the risks look like, and who it can help.
Gene delivery typically aims for a one-time treatment, since the new gene can keep producing protein indefinitely. Splicing-modifying drugs like Spinraza, on the other hand, require repeated doses because they work on RNA that the cell constantly produces and breaks down. Gene editing, if it successfully corrects the DNA, is also potentially permanent. All three approaches aim to restore missing protein function, and in many conditions, all three are being pursued simultaneously. In DMD, for example, researchers are testing viral gene delivery, CRISPR-based exon deletion, and oligonucleotide-based exon skipping, each targeting the same protein through a completely different mechanism.